• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION SYNERGY; BIODEGRADABLE POLYMER DRUG ELUTING CORONARY STENT SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION SYNERGY; BIODEGRADABLE POLYMER DRUG ELUTING CORONARY STENT SYSTEM Back to Search Results
Device Problem Obstruction of Flow (2423)
Patient Problem Reocclusion (1985)
Event Date 08/01/2018
Event Type  Injury  
Manufacturer Narrative
Hidekazu aoyama, et.Al., "midterm results after implantation of the 3rd generation des in our hospital and a study of in-stent covering by using oct." 2018-08-02, 9:45-10:45, 9, 4f 402.Device is combination product date of death and date of event: unknown, estimated as first day of publication month.(b)(6).
 
Event Description
It was reported via journal article that stent thrombosis occurred.This study enrolled 209 drug eluting stent patients (91 fast-release zotarolimus-eluting stents (zess), 40 slow-release zess, 37 durable polymer cobalt-chromium (cocr) everolimus-eluting stents (eess), 4 durable polymer platinum-chromium (ptcr) eess, 25 bioresorbable polymer ptcr eess (synergy), 12 bioresorbable polymer cocr sirolimus-eluting stents) from 135 patients (male 83%, age 69 plus or minus 10 years).They evaluated predictors for intra-stent thrombus by coronary angioscopy 4 months plus or minus 1 month after the implantation.Intra-stent thrombus was observed in 65 stents (31%).Multivariate analysis demonstrated that dyslipidemia, hemodialysis and fast-release zes implantation were associated with presence of intra stent thrombus.This result may indicate the need of dual antiplatelet therapy (dapt) continuation beyond 4 months for patients with hemodialysis and dyslipidemia, whereas we may safely switch dapt to single antiplatelet therapy in early phase for patients treated with fast-release zes.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNERGY
Type of Device
BIODEGRADABLE POLYMER DRUG ELUTING CORONARY STENT SYSTEM
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
Manufacturer (Section G)
BOSTON SCIENTIFIC IRELAND LIMITED
ballybrit business park
galway
EI  
Manufacturer Contact
sonali arangil
two scimed place
maple grove, MN 55311
6515827403
MDR Report Key8536054
MDR Text Key142636068
Report Number2134265-2019-04083
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Reporter Country CodeJA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Physician
Type of Report Initial
Report Date 04/22/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/22/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/29/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-